Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Non-Current Liabilities: 2016-2024

Historic Other Non-Current Liabilities for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $5.2 million.

  • Akebia Therapeutics' Other Non-Current Liabilities rose 10.89% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 10.89%. This contributed to the annual value of $5.2 million for FY2024, which is 41.47% down from last year.
  • According to the latest figures from FY2024, Akebia Therapeutics' Other Non-Current Liabilities is $5.2 million, which was down 41.47% from $8.9 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Other Non-Current Liabilities ranged from a high of $84.2 million in FY2021 and a low of $5.2 million during FY2024.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $8.9 million (2023), whereas its average is $9.9 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Other Non-Current Liabilities skyrocketed by 100.55% in 2020, and later crashed by 81.34% in 2022.
  • MRY analysis of 5 years shows Akebia Therapeutics' Other Non-Current Liabilities stood at $60.6 million in 2020, then skyrocketed by 38.94% to $84.2 million in 2021, then plummeted by 81.34% to $15.7 million in 2022, then plummeted by 43.47% to $8.9 million in 2023, then crashed by 41.47% to $5.2 million in 2024.
  • Its last three reported values are $5.2 million in FY2024, $8.9 million for FY2023, and $15.7 million during FY2022.